Search
Butyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl.
Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
SNX-5422
go.drugbank.com/drugs/DB06070InvestigationalAs an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Pelitinib
go.drugbank.com/drugs/DB05524InvestigationalPelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.
Synonyms: (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamideMPT0B640
go.drugbank.com/drugs/DB16512InvestigationalMPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.
Rumex salicifolius var. mexicanus pollen
go.drugbank.com/drugs/DB10902ApprovedRumex salicifolius var. mexicanus pollen is mainly used in allergenic testing.
Salix lucida ssp. lasiandra pollen
go.drugbank.com/drugs/DB10916ApprovedSalix lucida ssp. lasiandra pollen is mainly used in allergenic testing.
Sorghum bicolor subsp. bicolor pollen
go.drugbank.com/drugs/DB10965ApprovedSorghum bicolor subsp. bicolor pollen is mainly used in allergenic testing.
Sorghum bicolor subsp. drummondii pollen
go.drugbank.com/drugs/DB10966ApprovedSorghum bicolor subsp. drummondii pollen is mainly used in allergenic testing.
Poly(lactic acid)
go.drugbank.com/drugs/DB15037ApprovedInvestigationalWithdrawnPoly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).